News

Novartis posts better-than-expected sales driven by medicine demand
The Swiss pharma company also raised its full-year guidance, with sales expected to grow by high-single digits and core ...
Novartis Pharma AG: Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1
Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto ...
Novartis posts better-than-expected first-quarter sales, raises full-year guidance
Swiss pharmaceutical firm Novartis on Tuesday reported better-than-expected first-quarter sales and raised its full-year ...
The Manila Times6h
Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1
FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...
Shares Are Expensive With the Market Likely Extrapolating Telix's Current Sales Growth Rates
The solid cash conversion allows Telix to internally fund organic growth and flexibility to pursue acquisitions. We expect the company to reinvest the majority of earnings into R&D. We forecast ...
Cancer Therapy Advisor4d
FDA Roundup: Oncology Drug Approvals in 2025
On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.